Latest from Rush

New findings may lead to novel immunotherapies against third-deadliest cancer.
Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.
Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.
Shikha Jain, MD, hematologist/oncologist, Rush University Medical Center, discusses the disparities between male and female professionals at medical conferences, specifically the American Society of Clinical Oncology (ASCO) Annual Meeting.
Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.
Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.
Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.
Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.
Publication Bottom Border
Border Publication